An Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies

Trial Profile

An Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Cancer
  • Focus Therapeutic Use
  • Acronyms CheckMate 627
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 29 Mar 2017 Planned End Date changed from 1 Jan 2018 to 4 Jan 2019.
    • 06 Oct 2016 Status changed from not yet recruiting to recruiting.
    • 26 Jul 2016 Planned End Date changed from 1 Oct 2018 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top